Smithkline Beecham Corporation

Glaxosmithkline LLC

Glaxosmithkline Intellectual Property (no.2) Limited

Glaxo Wellcome Inc.

Glaxosmithkline Intellectual Property Development Limited

Astex Therapeutics Limited

Rodolfo Cadilla

Huiquiang Zhou

Michael Luzzio

Gordon Saxty

Brian Edward Marron

Joelle Le

Eugene Lee Stewart

Istvan Kaldor

Stephen Andrew Thomson

Philip Stewart Turnbull

Andrew Lamont Larkin

Millard Hurst Lambert, Iii

David John Cowan

Amarjit Sab Randhawa

Darryl Lynn McDougald

John Albert Ray

Stephen William Rafferty

David Lee Musso

Romain Luc Marie Gosmini

Jason Daniel Speake

Michael Joseph Bishop

Paul Kenneth Spearing

Daniel David Sternbach

Marcos Sznaidman

David Harold Drewry

Simon Teanby Hodgson

Michael Lawrence Sierra

Guosen Ye

Joseph Wendell Wilson

Robert Carl Andrews

Yue Li

Heather Hobbs

Ian Edward David Smith

Katherine Stetson

Brad Richard Henke

Cunyu Zhang

Gary Martin Green

Edward J Brnardic

Michael Jonathan Bury

Peter J Brown

Barry George Shearer

Christie Schulte

Frank Preugschat

Yu Guo

David Norman Deaton

Curt Haffner

Pierette Banker

Guangcheng Kevin Liu

Jennifer Susan Smith

Stewart Alwyn Noble

Maben Ying

Anthony Handlon

Huijie Li

Daniel Paone

Huichang Zhang

Jon Collins

J David Becherer

Paul N Mortenson

Huiqiang Zhou

Darryl Lynn Mcdougald

Ashley Paul Hancock

Daniel J Price

Lee T Schaller

Andrew L Larkin

Dave Norman Deaton

This invention relates to novel compounds according to Formula (I) which are antagonists of MrgX2, to pharmaceutical compositions containing them, and to their use in therapy for the treatment of MrgX2-mediated diseases and disorders.

MrgX2 antagonists

This invention relates to non-steroidal compounds that are modulators of androgen receptor, and also to the methods for the making and use of such compounds.

Chemical compounds

Compounds of Formula I and methods of treating diseases of metabolism by modulating cellular NAD+ levels through the inhibition of the CD38 enzyme, are disclosed. 

CD38 inhibitors and methods of treatment

Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.

Compounds as antagonists or inverse agonists of opioid receptors for treatment of addiction

Compounds as antagonists or inverse agonists at opioid receptors

This invention relates to benzonitryl and nitrobenzyl derivatives that are modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors, and also to the methods for the making and use of such compounds. These compounds are useful, for example, in the treatment or prophylaxis of conditions or disorders that respond to selective androgen receptor modulation.

Benzonitryl and nitrobenzyl derivatives that modulate androgen receptors

This invention relates to non-steroidal compounds that are modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors, and also to the methods for the making and use of such compounds.

Aniline derivatives as selective androgen receptor modulators

Growing community of inventors

Durham, NC, United States of America

Rodolfo Cadilla